Unione Europea - inglese - EMA (European Medicines Agency)

amgen europe b.v. - pegfilgrastim - neutropenia; cancer - immunostimulants, - reduction in the duration of neutropenia and the incidence of febrile neutropenia in patients treated with cytotoxic chemotherapy for malignancy (with the exception of chronic myeloid leukaemia and myelodysplastic syndromes).

Unione Europea - inglese - EMA (European Medicines Agency)

dompé biotec s.p.a. - pegfilgrastim - neutropenia; cancer - immunostimulants, - reduction in the duration of neutropenia and the incidence of febrile neutropenia in patients treated with cytotoxic chemotherapy for malignancy (with the exception of chronic myeloid leukaemia and myelodysplastic syndromes).

Unione Europea - inglese - EMA (European Medicines Agency)

amgen europe b.v. - pegfilgrastim - neutropenia - immunostimulants, - reduction in the duration of neutropenia and the incidence of febrile neutropenia in adult patients treated with cytotoxic chemotherapy for malignancy (with the exception of chronic myeloid leukaemia and myelodysplastic syndromes)

Australia - inglese - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - meropenem trihydrate, quantity: 570.5 mg (equivalent: meropenem, qty 500 mg) - injection, powder for - excipient ingredients: sodium carbonate - meropenem is indicated for treatment of the following infections, in adults and children (aged 3 months and over), when the causative organisms are known or suspected to be resistant to commonly used antibiotics: community acquired lower respiratory tract infection; hospital acquired lower respiratory tract infection; complicated urinary tract infection; febrile neutropenia; intra-abdominal and gynaecological (poly microbial) infections; complicated skin and skin structure infections; meningitis; septicaemia

Australia - inglese - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - meropenem trihydrate, quantity: 1141 mg (equivalent: meropenem, qty 1000 mg) - injection, powder for - excipient ingredients: sodium carbonate - meropenem is indicated for treatment of the following infections, in adults and children (aged 3 months and over), when the causative organisms are known or suspected to be resistant to commonly used antibiotics: community acquired lower respiratory tract infection; hospital acquired lower respiratory tract infection; complicated urinary tract infection; febrile neutropenia; intra-abdominal and gynaecological (poly microbial) infections; complicated skin and skin structure infections; meningitis; septicaemia

Australia - inglese - Department of Health (Therapeutic Goods Administration)

lupin australia pty limited - meropenem trihydrate, quantity: 570 mg (equivalent: meropenem, qty 500 mg) - injection, powder for - excipient ingredients: sodium carbonate - meropenem is indicated for treatment of the following infections, in adults and children (aged 3 months and over), when the causative organisms are known or suspected to be resistant to commonly used antibiotics: *community acquired lower respiratory tract infection *hospital acquired lower respiratory tract infection *complicated urinary tract infection *febrile neutropenia *intra-abdominal and gynaecological (poly microbial) infections *complicated skin and skin structure infections *meningitis *septicaemia

Australia - inglese - Department of Health (Therapeutic Goods Administration)

lupin australia pty limited - meropenem trihydrate, quantity: 1140 mg (equivalent: meropenem, qty 1000 mg) - injection, powder for - excipient ingredients: sodium carbonate - meropenem is indicated for treatment of the following infections, in adults and children (aged 3 months and over), when the causative organisms are known or suspected to be resistant to commonly used antibiotics: *community acquired lower respiratory tract infection *hospital acquired lower respiratory tract infection *complicated urinary tract infection *febrile neutropenia *intra-abdominal and gynaecological (poly microbial) infections *complicated skin and skin structure infections *meningitis *septicaemia

Australia - inglese - Department of Health (Therapeutic Goods Administration)

lupin australia pty limited - meropenem trihydrate, quantity: 1140 mg (equivalent: meropenem, qty 1000 mg) - injection, powder for - excipient ingredients: sodium carbonate - meropenem is indicated for treatment of the following infections, in adults and children (aged 3 months and over), when the causative organisms are known or suspected to be resistant to commonly used antibiotics: *community acquired lower respiratory tract infection *hospital acquired lower respiratory tract infection *complicated urinary tract infection *febrile neutropenia *intra-abdominal and gynaecological (poly microbial) infections *complicated skin and skin structure infections *meningitis *septicaemia

Australia - inglese - Department of Health (Therapeutic Goods Administration)

lupin australia pty limited - meropenem trihydrate, quantity: 570 mg (equivalent: meropenem, qty 500 mg) - injection, powder for - excipient ingredients: sodium carbonate - meropenem is indicated for treatment of the following infections, in adults and children (aged 3 months and over), when the causative organisms are known or suspected to be resistant to commonly used antibiotics: *community acquired lower respiratory tract infection *hospital acquired lower respiratory tract infection *complicated urinary tract infection *febrile neutropenia *intra-abdominal and gynaecological (poly microbial) infections *complicated skin and skin structure infections *meningitis *septicaemia

Australia - inglese - Department of Health (Therapeutic Goods Administration)

sun pharma anz pty ltd - meropenem trihydrate, quantity: 570 mg (equivalent: meropenem, qty 500 mg) - injection, powder for - excipient ingredients: sodium carbonate - meropenem ranbaxy is indicated for the treatment of the following infections, in adults and children (aged 3 months and over), when the causative organisms are known or suspected to be resistant to commonly used antibiotics: - community acquired lower respiratory tract infection, - hospital acquired lower respiratory tract infection, - complicated urinary tract infection, - febrile neutropenia, - intra-abdominal and gynaecological (polymicrobial) infections, - complicated skin and skin structure infections, - meningitis, - septicaemia.